|Table of Contents|

Expression level of lncRNA NORAD in ovarian cancer tissues and its correlation with clinicopathological features and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 01
Page:
152-155
Research Field:
Publishing date:

Info

Title:
Expression level of lncRNA NORAD in ovarian cancer tissues and its correlation with clinicopathological features and prognosis
Author(s):
SUI Lei1; JI Xiaoyu1; ZHU Xiaoying1; DU Xiuzhen1; YOU Shijing1; YAO Qin2
1.Medical College,Qingdao University,Shandong Qingdao 266071,China;2.Department of Gynecology,the Affiliated Hospital of Qingdao University,Shandong Qingdao 266071,China.
Keywords:
ovarian carcinoma; NORAD; prognosis; Kaplan-Meier plotter database
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.01.028
Abstract:
Objective:To investigate the correlation between the expression level of non-coding RNA activated by DNA damage(NORAD) in ovarian cancer tissues and clinicopathological features and prognosis.Methods:Tissue specimens from 50 patients with ovarian cancer and 50 patients with normal ovaries who were diagnosed and treated in the Affiliated Hospital of Qingdao University from 2019 to 2020 were selected.The relative expression level of NORAD in the tissues of the above patients was detected by real-time quantitative reverse transcription polymerase chain reaction(qRT-PCR) method,and the relationship between the expression level of NORAD and clinicopathological characteristics and prognostic value were analyzed.The association of NORAD expression with ovarian cancer prognosis was assessed using the Kaplan-Meier plotter online database.Results:NORAD was highly expressed in ovarian cancer tissues.The high expression of NORAD in ovarian cancer tissues was correlated with FIGO stage,tumor histotype,ascites and lymph nodes metastasis(P＜0.05).The 5-year progression-free survival(PFS) of ovarian cancer patients with high NORAD expression was significantly lower than that of the low expression group.The expression level of NORAD in ovarian cancer tissue had an evaluation value for the prognosis of patients in FIGO stage,pathological grade,TP53 status and chemotherapy treatment.Conclusion:The expression level of NORAD in ovarian cancer tissue is significantly increased,and its level is related to the clinicopathological characteristics and prognosis of ovarian cancer.

References:

［1］SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA:A Cancer Journal for Clinicians,2020,70(1):7-30.
［2］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin, 2021,71(3):209-249.
［3］EISENHAUER EA.Real-world evidence in the treatment of ovarian cancer［J］.Ann Oncol,2017,28(suppl_8):viii61-viii65.
［4］GIL N,ULITSKY I.Regulation of gene expression by cis-acting long non-coding RNAs［J］.Nat Rev Genet,2020,21(2):102-117.
［5］LEE S,KOPP F,CHANG TC,et al.Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins［J］.Cell,2016,164(1-2):69-80.
［6］YANG Z,ZHAO Y,LIN G,et al.Noncoding RNA activated by DNA damage(NORAD):Biologic function and mechanisms in human cancers［J］.Clinica Chimica Acta,International Journal of Clinical Chemistry,2019,489:5-9.
［7］WU Y,SHEN QW,NIU YX,et al.LncNORAD interference inhibits tumor growth and lung cancer cell proliferation,invasion and migration by down-regulating CXCR4 to suppress RhoA/ROCK signaling pathway［J］.Eur Rev Med Pharmacol Sci,2020,24(10):5446-5455.
［8］XU C,ZHU LX,SUN DM,et al.Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p［J］.European Review for Medical and Pharmacological Sciences,2020,24(4):1672-1681.
［9］TONG L,AO Y,ZHANG H,et al.Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p［J］.Cancer Medicine,2019,8(10):4782-4791.
［10］WANG Q,ZHANG Q,WANG J,et al.Prognostic and clinicopathological role of long noncoding RNA NORAD in various cancers:a meta-analysis［J］.Biomark Med,2021,15(6):427-436.
［11］YE T,YE Z.LncRNA NORAD as a novel predictor of lymph node metastasis and prognosis in solid tumors:A systematic review and Meta-analysis［J］.Technology in Cancer Research & Treatment,2020,19:1533033820963586.
［12］BRAGA EA,FRIDMAN MV,MOSCOVTSEV AA,et al.LncRNAs in ovarian cancer progression,metastasis,and main pathways:ceRNA and alternative mechanisms［J］.Int J Mol Sci,2020,21(22):8855.
［13］SALAMINI-MONTEMURRI M,LAMAS-MACEIRAS M,BARREIRO-ALONSO A,et al.The challenges and opportunities of lncRNAs in ovarian cancer research and clinical use［J］.Cancers(Basel),2020,12(4):1020.
［14］LAI ZY,TSAI KY,CHANG SJ,et al.Gain-of-function mutant TP53 R248Q overexpressed in epithelial ovarian carcinoma alters AKT-dependent regulation of intercellular trafficking in responses to EGFR/MDM2 inhibitor［J］.International Journal of Molecular Sciences,2021,22(16):8784.
［15］LAWSON BC,YANG RK,EUSCHER ED,et al.TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma［J］.Human Pathology,2021,115:76-83.
［16］WATANABE T,NANAMIYA H,ENDO Y,et al.Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer［J］.Journal of Ovarian Research,2021,14(1):129.

Memo

Memo:
山东省自然科学基金（编号：ZR2016HM08）；山东省青岛市民生科技计划资助项目（编号:19-6-46-nsh）
Last Update: 2022-11-30